Pfizer reports 62.5% EASI-75 response for tilrekimig in Phase 2 trial
AI Summary- Pfizer presented Phase 2 tilrekimig results in adults with moderate-to-severe atopic dermatitis.
- 62.5% achieved EASI-75 with 450 mg every two weeks, versus 19.9% on placebo.
- Tilrekimig showed no dose-dependent safety signals and supported monthly dosing in Stage 2.